Overview

Renal Mechanism of Action/Splay vs. TmG

Status:
Terminated

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Dapagliflozin